Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide in Adults With T2DM
NCT06660173Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised trial in type 2 diabetes mellitus (T2DM) comparing Maridebart Cafraglutide with Placebo (2 arms). Primary endpoint: Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c). Started Nov 2024; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06660173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660173.